{rfName}
Cu

Indexed in

License and use

Citations

2

Altmetrics

Grant support

This work was supported by Global Perspectives on Addictions and Drug Markets (Inter-GLAM), an international project, and co-funded by Grant No. 957776 under the European Union's Directorate General for Justice (DG Justice) Programme "Drugs Policy Initiatives - Supporting initiatives in the field of drugs policy" (JUST-2019-AG-DRUGS) from 1 July 2021 to 30 June 2023.

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Folch-Sanchez, DanielAuthorBraddick, FleurAuthorBatalla, AlbertAuthor

Share

March 1, 2025
Publications
>
Review
No

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges

Publicated to:Cns Drugs. 38 (10): 771-789 - 2024-07-20 38(10), DOI: 10.1007/s40263-024-01101-3

Authors: Gomez-Escolar, Anton; Folch-Sanchez, Daniel; Stefaniuk, Joanna; Swithenbank, Zoe; Nisa, Andreia; Braddick, Fleur; Chaudhary, Nazish Idrees; van der Meer, Pim B; Batalla, Albert

Affiliations

Asociac Bienestar & Desarrollo ABD, Energy Control, Madrid, Spain - Author
Assoc Existencias, RECI, Viseu, Portugal - Author
Clin Fdn Biomed Res, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS, Addict Res Grp GRAC, Barcelona, Spain - Author
Drogopedia, Madrid, Spain - Author
INAWE Inst, Calle Ciudad Real 28, Madrid 28223, Spain - Author
Liverpool John Moores Univ, Publ Hlth Inst, Liverpool, England - Author
Polish Drug Policy Network, Warsaw, Poland - Author
Soc Espanola Med Psicodel SEMPsi, Barcelona, Spain - Author
Univ Lahore, Lahore Sch Behav Sci LSBS, Lahore, Pakistan - Author
Univ Med Ctr, Dept Neurol, Leiden, Netherlands - Author
Univ Utrecht, Univ Med Ctr, Dept Psychiat, Utrecht Brain Ctr, Utrecht, Netherlands - Author
See more

Abstract

Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical evidence than for other mental health disorders, such as depression or post-traumatic stress disorder (PTSD). In this narrative review, we discuss the current clinical research evidence, therapeutic potential and safety of psilocybin, lysergic acid diethylamide (LSD), ketamine, 3,4-methylenedioxymethamphetamine (MDMA) and ibogaine, particularly in the context of the SUD treatment. Our aim was to provide a balanced overview of the current research and findings on potential benefits and harms of psychedelics in clinical settings for SUD treatment. We highlight the need for more clinical research in this particular treatment area and point out some limitations and challenges to be addressed in future research.

Keywords

AddictionAyahuascaBiomedical researchBraiClinical researchDepressionDouble-blindDrug dependenceDrug therapyFollow-upGlobal disease burdenGood health and well-beingHallucinogensHumanHumansIbogaineKetamineLysergideMdmaMebufoteninMedical researchMedicalizationMental healthMidomafetaminePosttraumatic stress disorderPsilocybinPsilocybinePsychedelic agentReviewSingleSubstance-related disordersTherapyTreatment-resistant depressionUse disorder

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cns Drugs due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 17/280, thus managing to position itself as a Q1 (Primer Cuartil), in the category Clinical Neurology. Notably, the journal is positioned above the 90th percentile.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 27.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 63 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 83.7.
  • The number of mentions on the social network X (formerly Twitter): 15 (Altmetric).
  • The number of mentions on Wikipedia: 1 (Altmetric).
  • The number of mentions in news outlets: 8 (Altmetric).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Good Health And Well-being, with a probability of 80% according to the mBERT algorithm developed by Aurora University.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Netherlands; Pakistan; Poland; Portugal; United Kingdom.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Batalla Cases, Albert).